Attitudes of African-Americans regarding prostate cancer clinical trials
- 104 Downloads
The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio-economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues.
Unable to display preview. Download preview PDF.
- 1.American Cancer Society. Cancer Facts and Figures 1995.American Cancer Society, Incorporation. Publication No. 5008, 1995, pp 10–12.Google Scholar
- 2.Miller BA, Ries LAG, Hankely BF, Kosary CL, Harras A, Devesa SS, and Edward BK (Eds).SEER Cancer Statistics Review: 1973–1990, National Cancer Institute. NIH Publication No. 93-2789, 1994.Google Scholar
- 3.Kurihara M, Aoki K, and Hisamichi S (Eds).Cancer Mortality Statistics in the World 1950–1985. Nagoya, Japan; University of Nagoya Press, 1984.Google Scholar
- 5.Moskovitz B, Nitecki A, and Richter L. Cancer of the prostate: is there a need for aggressive treatment?Urology Int 1987; 42:49–52.Google Scholar
- 9.Elder J, Jeweet H, and Walsh P. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate.J Urol 1983; 127:704–706.Google Scholar
- 17.Begg CV, Carborbe PP, Elson PJ, and et al. Participation of community hospitals in clinical trials: analysis of five years of experience in the Eastern Cooperative Oncology Group.New England J Med 1983; 306:1076–1080.Google Scholar
- 18.Hunter CP, Frelick RW, Feldman AR, and et al. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log.Cancer Treat Reports 1987; 71: 559–563.Google Scholar
- 19.Barbie, E.The Practice of Social Research. Belmont, CA: Wadsworth, 1989, pp. 20–29.Google Scholar
- 20.Dignan M, Michielutte R, Sharp P, Bahnson J, Young L, and Beal P. The role of focus groups in health education programs for cervical cancer among minority groups.J Comm Health 1990; 15:369–375.Google Scholar
- 21.Morgan DL, and Kruger RA. When to Use Focus Groups and Why? In. Morgan DL (Ed).Successful Focus Groups: Advancing the State of the Art. Sage Publications, Newburg CA: 1993, pp 3–19.Google Scholar
- 23.Davis SW, Nealson ED, and Stone JC. Evaluation of the National Cancer Institute's Clinical Trial Booklet.Journal of the National Cancer Institute Monographs 1993; 14:193–195.Google Scholar
- 24.Polednak AP and Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostate cancer in Connecticut.Cancer 1993; 70:2152–2158.Google Scholar